Microbot Medical Inc. announced on April 9, 2025, the presentation of data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study, conducted at three leading U.S. medical centers, demonstrated significant positive outcomes for the LIBERTY Endovascular Robotic System.
The data presented concluded that robotic endovascular procedures using LIBERTY are feasible and significantly minimize radiation exposure. The study achieved 100% robotic navigation success in every case, meeting the primary endpoint, and showed a 92% reduction in radiation exposure for physicians.
Furthermore, no adverse events were reported during the trial, highlighting the safety profile of the LIBERTY system. These strong clinical results are expected to be well received in the market and are crucial for supporting the ongoing FDA 510(k) clearance process and subsequent commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.